These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 7987928)

  • 1. [Nootropic drugs and their action mechanisms in relation to the neuropathobiology of senile dementia. I. Neurotransmission disorders in the brain].
    Benesová O
    Cesk Psychiatr; 1994 Aug; 90(4):191-200. PubMed ID: 7987928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropathobiology of senile dementia and mechanism of action of nootropic drugs.
    Benesová O
    Drugs Aging; 1994 Apr; 4(4):285-303. PubMed ID: 8019052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nootropics: pharmacological properties and therapeutic use.
    Gabryel B; Trzeciak HI
    Pol J Pharmacol; 1994; 46(5):383-94. PubMed ID: 7894524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy approaches in cerebral cognitive deficits--neuropsychiatric aspects].
    Reisecker F
    Wien Med Wochenschr; 1996; 146(21-22):546-8. PubMed ID: 9092214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nooptropic agents and their action mechanisms in relation to neuropathology in senile dementia. II. Disorders of membrane integrity and neuron metabolism].
    Benesová O
    Cesk Psychiatr; 1994 Oct; 90(5):251-61. PubMed ID: 7850909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. length of clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Levy R
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():33. PubMed ID: 9305513
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art.
    Fariello RG
    Funct Neurol; 1997; 12(3-4):221-5. PubMed ID: 9218984
    [No Abstract]   [Full Text] [Related]  

  • 8. CDP-choline: pharmacological and clinical review.
    Secades JJ; Frontera G
    Methods Find Exp Clin Pharmacol; 1995 Oct; 17 Suppl B():1-54. PubMed ID: 8709678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholinesterase inhibitors in the treatment of Alzheimer's disease and related dementias.
    Masterman D
    Clin Geriatr Med; 2004 Feb; 20(1):59-68. PubMed ID: 15062487
    [No Abstract]   [Full Text] [Related]  

  • 10. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl).
    Maelicke A
    Int J Clin Pract Suppl; 2001 May; (120):24-8. PubMed ID: 11406923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of nootropic potential of Ocimum sanctum Linn. in mice.
    Joshi H; Parle M
    Indian J Exp Biol; 2006 Feb; 44(2):133-6. PubMed ID: 16480180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer disease and its management: a review.
    Samanta MK; Wilson B; Santhi K; Kumar KP; Suresh B
    Am J Ther; 2006; 13(6):516-26. PubMed ID: 17122533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
    Prasher VP
    Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Alzheimer's disease].
    Giménez-Roldán S
    Rev Neurol; 1995; 23(119):96-102. PubMed ID: 8548651
    [No Abstract]   [Full Text] [Related]  

  • 15. Translation issues in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Feldman H; Anand R; Blesa R; Dubois B; Gray J; Homma A; Mohr E; Morris JC; Parys W; Raschig A; Robillard A
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():61-4. PubMed ID: 9305520
    [No Abstract]   [Full Text] [Related]  

  • 16. Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Gauthier S; Bodick N; Erzigkeit E; Feldman H; Geldmacher DS; Huff J; Mohs R; Orgogozo JM; Rogers S
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():6-7. PubMed ID: 9305507
    [No Abstract]   [Full Text] [Related]  

  • 17. Lines of therapeutics research in Alzheimer's disease.
    Shvaloff A; Neuman E; Guez D
    Psychopharmacol Bull; 1996; 32(3):343-52. PubMed ID: 8961777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dementing disorders. What benefits do the new anti-dementia drugs have?].
    Ihl R
    MMW Fortschr Med; 2002 May; Suppl 2():24-6, 28-9. PubMed ID: 12070846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia].
    Tariska P; Paksy A
    Orv Hetil; 2000 May; 141(22):1189-93. PubMed ID: 10853348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse Lewy body disease: a common yet misdiagnosed dementia in which neuroleptics may be contraindicated.
    Scarbrough TJ
    Tenn Med; 1998 Feb; 91(2):58-60. PubMed ID: 9478123
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.